All In Biotech

NDA 220837 · Apotex

Evdi

Trabectedin · Intravenous · Alkylating Drug

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

May 1, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

89

18 Phase 3, 12 recruiting

FAERS reports

1,205

1,178 serious, 261 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 29, 2026.

EVDI is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] . EVDI is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )

Mechanism: Trabectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 1, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
1 products under this application
  • EVDI · TRABECTEDIN 1MG/20ML (0.05MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trabectedin" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia159
  • anaemia133
  • thrombocytopenia132
  • disease progression118
  • nausea109
  • febrile neutropenia107
  • drug ineffective93
  • vomiting92
  • off label use86
  • asthenia72
  • fatigue66
  • pancytopenia64

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20073
20083
20092
201011
201132
201219
201312
201414
201548
2016101
201791
2018121
2019127
202094
202171
202288
2023100
2024107
202577
202683

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 123 on PubMed

Sponsor: Apotex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.